UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):May 15, 2015 (May 12, 2015)
_________________________
VBI VACCINES INC.
(Exact name of registrant as specified in charter)
Delaware | | 000-18188 | | 93-0589534 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
222 3rd Street, Suite 2241
Cambridge, Massachusetts 02142
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 830-3031
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below).
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
[ ] Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 12, 2015, VBI Vaccines Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders. At the meeting, the stockholders voted to: (1) elect seven directors; (2) approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation; (3) approve, on advisory basis, the compensation of our named executive officers; and (4) the ratification of the appointment of Peterson Sullivan LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015. The voting results on these proposals were as follows:
Proposal 1: Election of Seven Directors
Director | Votes For | Withheld | Broker Non-Votes |
Jeff R. Baxter FCMA | 14,545,514 | 19,403 | 1,272,348 |
Sam Chawla | 14,545,864 | 19,053 | 1,272,348 |
Trent D. Davis | 14,385,665 | 179,262 | 1,272,348 |
Michel De Wilde, Ph.D. | 14,564,337 | 580 | 1,272,348 |
Steven Gillis Ph.D. | 14,564,337 | 580 | 1,272,348 |
Michael Steinmetz Ph.D. | 14,546,124 | 18,793 | 1,272,348 |
Alan P. Timmins | 14,564,337 | 580 | 1,272,348 |
Proposal 2: Approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation
1 year | 2 years | 3 years | Abstentions | Broker Non-Votes |
14,556,181 | 702 | 480 | 7,554 | 1,272,348 |
Proposal 3: Approve, on advisory basis, the compensation of our named executive officers
Votes For | Votes Against | Abstentions | Broker Non-Votes |
14,550,557 | 8,080 | 6,280 | 1,272,348 |
Proposal 4: Ratification of the appointment ofPeterson Sullivan LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015
Votes For | Votes Against | Abstentions |
15,834,330 | 2,935 | 0 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VBI VACCINES INC. | |
| | |
| | |
| | | |
Date: May 15, 2015 | By: | /s/ Jeff Baxter | |
| | Jeff Baxter Chief Executive Officer | |
